These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L. Am J Kidney Dis; 2007 Dec; 50(6):908-17. PubMed ID: 18037091 [Abstract] [Full Text] [Related]
23. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160). Ogawa H, Kim-Mitsuyama S, Jinnouchi T, Matsui K, Arakawa K. Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280 [Abstract] [Full Text] [Related]
25. Ambulatory versus clinic blood pressure for the assessment of anti hypertensive efficacy in clinical trials: insights from the Val-Syst Study. Palatini P, Dorigatti F, Mugellini A, Spagnuolo V, Varì N, Ferrara R, Bertocchi F. Clin Ther; 2004 Sep; 26(9):1436-45. PubMed ID: 15531006 [Abstract] [Full Text] [Related]
26. Pulse pressure monitoring of open antihypertensive therapy. Safar ME, Vaisse B, Blacher J, Rudnichi A, Mourad JJ. Am J Hypertens; 2004 Dec; 17(12 Pt 1):1088-94. PubMed ID: 15607613 [Abstract] [Full Text] [Related]
27. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. Knudsen ST, Andersen NH, Poulsen SH, Eiskjaer H, Hansen KW, Helleberg K, Poulsen PL, Mogensen CE. Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164 [Abstract] [Full Text] [Related]
28. [Arterial hypertension difficult to control in the elderly patient. The significance of the "white coat effect"]. Amado P, Vasconcelos N, Santos I, Almeida L, Nazaré J, Carmona J. Rev Port Cardiol; 1999 Oct; 18(10):897-906. PubMed ID: 10590654 [Abstract] [Full Text] [Related]
32. Effects of the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood pressure in hypertension: evidence from a large database. Mancia G, Omboni S, Chazova I, Coca A, Girerd X, Haller H, Parati G, Pauletto P, Pupek-Musialik D, Svyshchenko Y, FELT Study Group. J Hypertens; 2016 Jan; 34(1):139-48. PubMed ID: 26630216 [Abstract] [Full Text] [Related]
33. Impact of blood pressure control and angiotensin-converting enzyme inhibitor therapy on new-onset microalbuminuria in type 2 diabetes: a post hoc analysis of the BENEDICT trial. Ruggenenti P, Perna A, Ganeva M, Ene-Iordache B, Remuzzi G, BENEDICT Study Group. J Am Soc Nephrol; 2006 Dec; 17(12):3472-81. PubMed ID: 17082240 [Abstract] [Full Text] [Related]
39. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, Skoog I, Trenkwalder P, Zanchetti A, Study on Cognition and Prognosis in the Elderly study group. J Am Coll Cardiol; 2004 Sep 15; 44(6):1175-80. PubMed ID: 15364316 [Abstract] [Full Text] [Related]